Influence of DNA damage and repair upon the risk of treatment related leukemia

Leukemia and Lymphoma

Volumn 49, Issue 2, 2008, Pages 204-217

  Guillem, Vicent ^a   Tormo, Mar ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Alkylating; Antimetabolites; DNA repair; Secondary leukemia; SNP; t MDS AML; Topoisomerase II inhibitors

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC ANTIMETABOLITE; BLEOMYCIN; CAPECITABINE; CHLORMETHINE; CHLOROETHYLNITROSOUREA; CISPLATIN DERIVATIVE; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DAUNORUBICIN; DNA; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; FOLIC ACID; GYRASE INHIBITOR; MELPHALAN; METHOTREXATE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MITOXANTRONE; NUCLEOTIDE; PROCARBAZINE; RAD51 PROTEIN; SULFONIC ACID DERIVATIVE; TENIPOSIDE; THYMIDYLATE SYNTHASE; UNINDEXED DRUG; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CHROMOSOME ABERRATION; DNA DAMAGE; DNA REPAIR; DNA SYNTHESIS; DRUG DETOXIFICATION; DRUG EXPOSURE; DRUG MECHANISM; DRUG METABOLISM; FOLATE METABOLISM; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENOTYPE; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMOGENESIS; MYELODYSPLASIA; NUCLEOTIDE METABOLISM; PRIORITY JOURNAL; RADIATION EXPOSURE; REVIEW; SOLID TUMOR;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; DNA DAMAGE; DNA REPAIR; DNA TOPOISOMERASES, TYPE II; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASMS, SECOND PRIMARY; POLYMORPHISM, GENETIC;

EID: 38849123474     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701769657     Document Type: Review

References (111)

1. Smith, S. M., Beau, M M Le, Huo, D., Karrison, T., Sobecks, R. M. and Anastasi, J. (2003) Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: The University of Chicago series. Blood, 102, pp. 43-52.
2. Qian, Z., Fernald, A. A., Godley, L. A., Larson, R. A. and Beau, M M Le (2002) Expression profiling of CD34+ hematopoietic stem/progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia. Proc Natl Acad Sci USA, 99, pp. 14925-14930.
3. Pedersen-Bjergaard, J., Christiansen, D. H., Desta, F. and Andersen, M. K. (2006) Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia, 20, pp. 1943-1949.
4. Leone, G., Voso, M. T., Sica, S., Morosetti, R. and Pagano, L. (2001) Therapy related leukemias: Susceptibility, prevention and treatment. Leuk Lymphoma, 41, pp. 255-276.
5. Rund, D. and Ben-Yehuda, D. (2004) Therapy-related leukemia and myelodysplasia: Evolving concepts of pathogenesis and treatment. Hematology, 9, pp. 179-187.
6. Turker, A. and Guler, N. (1999) Therapy related acute myeloid leukemia after exposure to 5-fluorouracil: A case report. Hematol Cell Ther, 41, pp. 195-196.
7. Tam, C. S., Seymour, J. F., Prince, H. M., Kenealy, M., Wolf, M., Januszewicz, E. H. and Westerman, D. (2006) Treatment-related myelodysplasia following fludarabine combination chemotherapy. Haematologica, 91, pp. 1546-1550.
8. Khan, S. G., Muniz-Medina, V., Shahlavi, T., Baker, C. C., Inui, H., Ueda, T., Emmert, S., Schneider, T. D. and Kraemer, K. H. (2002) The human XPC DNA repair gene: Arrangement, splice site information content and influence of a single nucleotide polymorphism in a splice acceptor site on alternative splicing and function. Nucleic Acids Res, 30, pp. 3624-3631.
9. Vaish, M. (2007) Mismatch repair deficiencies transforming stem cells into cancer stem cells and therapeutic implications. Mol Cancer, 6, p. 26.
10. Rai, R., Peng, G., Li, K. and Lin, S. Y. (2007) DNA damage response: The players, the network and the role in tumor suppression. Cancer Genomics Proteomics, 4, pp. 99-106.
11. Reese, J. S., Liu, L. and Gerson, S. L. (2003) Repopulating defect of mismatch repair-deficient hematopoietic stem cells. Blood, 102, pp. 1626-1633.
12. Grossman, L., Matanoski, G., Farmer, E., Hedayati, M., Ray, S. and Trock, B. (1999) DNA repair as a susceptibility factor in chronic diseases in human populations. Advances in DNA Damage and Repair, pp. 149-167. Kluwer Academic/Plenum Publishers, New York
13. Wood, R. D., Mitchell, M. and Lindahl, T. (2005) Human DNA repair genes, 2005. Mutat Res, 577, pp. 275-283.
14. Chaney, S. G. and Sancar, A. (1996) DNA repair: Enzymatic mechanisms and relevance to drug response. J Natl Cancer Inst, 88, pp. 1346-1360.
15. Spry, M., Scott, T., Pierce, H. and D'Orazio, J. A. (2007) DNA repair pathways and hereditary cancer susceptibility syndromes. Front Biosci, 12, pp. 4191-4207.
16. Squire, J. A., Whitmore, G. F. and Phillips, R. A. (1998) Genetic basis of cancer. The Basic Science of Oncology, pp. 48-78. McGraw-Hill Press, New York
17. Iliakis, G., Wang, H., Perrault, A. R., Boecker, W., Rosidi, B. and Windhofer, F. (2004) Mechanisms of DNA double strand break repair and chromosome aberration formation. Cytogenet Genome Res, 104, pp. 14-20.
18. Chu, G. (1997) Double strand break repair. J Biol Chem, 272, pp. 24097-24100.
19. Goode, E. L., Ulrich, C. M. and Potter, J. D. (2002) Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev, 11, pp. 1513-1530.
20. Rothkamm, K., Kruger, I., Thompson, L. H. and Lobrich, M. (2003) Pathways of DNA double-strand break repair during the mammalian cell cycle. Mol Cell Biol, 23, pp. 5706-5715.
21. Dai, Y., Kysela, B., Hanakahi, L. A., Manolis, K., Riballo, E. and Stumm, M. (2003) Nonhomologous end joining and V(D)J recombination require an additional factor. Proc Natl Acad Sci USA, 100, pp. 2462-2467.
22. Arnaudeau, C., Lundin, C. and Helleday, T. (2001) DNA double-strand breaks associated with replication forks are predominantly repaired by homologous recombination involving an exchange mechanism in mammalian cells. J Mol Biol, 307, pp. 1235-1245.
23. Hortobagyi, G. N. (1997) Anthracyclines in the treatment of cancer. An overview. Drugs, 54, pp. 1-7.
24. Felix, C. A. (1998) Secondary leukemias induced by topoisomerase-targeted drugs. Biochim Biophys Acta, 1400, pp. 233-255.
25. Pfeiffer, P., Goedecke, W. and Obe, G. (2000) Mechanisms of DNA double-strand break repair and their potential to induce chromosomal aberrations. Mutagenesis, 15, pp. 289-302.
26. Larsen, A. K., Escargueil, A. E. and Skladanowski, A. (2003) From DNA damage to G2 arrest: The many roles of topoisomerase II. Prog Cell Cycle Res, 5, pp. 295-300.
27. Lovett, B. D., Strumberg, D., Blair, I. A., Pang, S., Burden, D. A. and Megonigal, M. D. (2001) Etoposide metabolites enhance DNA topoisomerase II cleavage near leukemia-associated MLL translocation breakpoints. Biochemistry, 40, pp. 1159-1170.
28. Stanulla, M., Wang, J., Chervinsky, D. S. and Aplan, P. D. (1997) Topoisomerase II inhibitors induce DNA double-strand breaks at a specific site within the AML1 locus. Leukemia, 11, pp. 490-496.
29. Mistry, A. R., Felix, C. A., Whitmarsh, R. J., Mason, A., Reiter, A. and Cassinat, B. (2005) DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N Engl J Med, 352, pp. 1529-1538.
30. Nishiyama, M., Arai, Y., Tsunematsu, Y., Kobayashi, H., Asami, K. and Yabe, M. (1999) 11p15 translocations involving the NUP98 gene in childhood therapy-related acute myeloid leukemia/myelodysplastic syndrome. Genes Chromosomes Cancer, 26, pp. 215-220.
31. Strissel, P. L., Strick, R., Rowley, J. D. and Zeleznik-Le, N. J. (1998) An in vivo topoisomerase II cleavage site and a DNase I hypersensitive site colocalize near exon 9 in the MLL breakpoint cluster region. Blood, 92, pp. 3793-3803.
32. Tewey, K. M., Chen, G. L., Nelson, E. M. and Liu, L. F. (1984) Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem, 259, pp. 9182-9187.
33. Pedersen-Bjergaard, J. (2005) Insights into leukemogenesis from therapy-related leukemia. N Engl J Med, 352, pp. 1591-1594.
34. Beranek, D. T., Weis, C. C. and Swenson, D. H. (1980) A comprehensive quantitative analysis of methylated and ethylated DNA using high pressure liquid chromatography. Carcinogenesis, 1, pp. 595-606.
35. Engelward, B. P., Allan, J. M., Dreslin, A. J., Kelly, J. D., Wu, M. M., Gold, B. and Samson, L. D. (1998) A chemical and genetic approach together define the biological consequences of 3-methyladenine lesions in the mammalian genome. J Biol Chem, 273, pp. 5412-5418.
36. Liu, L., Nakatsuru, Y. and Gerson, S. L. (2002) Base excision repair as a therapeutic target in colon cancer. Clin Cancer Res, 8, pp. 2985-2991.
37. Chen, F. X., Zhang, Y., Church, K. M., Bodell, W. J. and Gold, B. (1993) DNA crosslinking, sister chromatid exchange and cytotoxicity of N-2-chloroethylnitrosoureas tethered to minor groove binding peptides. Carcinogenesis, 14, pp. 935-940.
38. Ludlum, D. B. (1990) DNA alkylation by the haloethylnitrosoureas: Nature of modifications produced and their enzymatic repair or removal. Mutat Res, 233, pp. 117-126.
39. Curtis, R. E., Boice Jr, J. D., Stovall, M., Bernstein, L., Greenberg, R. S. and Flannery, J. T. (1992) Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med, 326, pp. 1745-1751.
40. Povirk, L. F. and Shuker, D. E. (1994) DNA damage and mutagenesis induced by nitrogen mustards. Mutat Res, 318, pp. 205-226.
41. Hansson, J., Lewensohn, R., Ringborg, U. and Nilsson, B. (1987) Formation and removal of DNA cross-links induced by melphalan and nitrogen mustard in relation to drug-induced cytotoxicity in human melanoma cells. Cancer Res, 47, pp. 2631-2637.
42. Worrillow, L. J. and Allan, J. M. (2006) Deregulation of homologous recombination DNA repair in alkylating agent-treated stem cell clones: A possible role in the aetiology of chemotherapy-induced leukaemia. Oncogene, 25, pp. 1709-1720.
43. Mamuris, Z., Prieur, M., Dutrillaux, B. and Aurias, A. (1989) The chemotherapeutic drug melphalan induces breakage of chromosomes regions rearranged in secondary leukemia. Cancer Genet Cytogenet, 37, pp. 65-77.
44. Andersen, M. K., Christiansen, D. H. and Pedersen-Bjergaard, J. (2005) Centromeric breakage and highly rearranged chromosome derivatives associated with mutations of TP53 are common in therapy-related MDS and AML after therapy with alkylating agents: An M-FISH study. Genes Chromosomes Cancer, 42, pp. 358-371.
45. Lessard, M., Herry, A., Berthou, C., Leglise, M. C., Abgrall, J. F. and Morice, P. (1998) FISH investigation of 5q and 7q deletions in MDS/AML reveals hidden translocations, insertions and fragmentations of the same chromosomes. Leuk Res, 22, pp. 303-312.
46. Agarwal, S., Tafel, A. A. and Kanaar, R. (2006) DNA double-strand break repair and chromosome translocations. DNA Repair (Amst), 5, pp. 1075-1081.
47. Drablos, F., Feyzi, E., Aas, P. A., Vaagbo, C. B., Kavli, B., Bratlie, M. S., Pena-Diaz, J., Otterlei, M., Slupphaug, G. and Krokan, H. E. (2004) Alkylation damage in DNA and RNA-repair mechanisms and medical significance. DNA Repair (Amst), 3, pp. 1389-1407.
48. Kobune, M., Xu, Y., Baum, C., Kelley, M. R. and Williams, D. A. (2001) Retrovirus-mediated expression of the base excision repair proteins, formamidopyrimidine DNA glycosylase or human oxoguanine DNA glycosylase, protects hematopoietic cells from N,N',N''-triethylenethiophosphoramide (thioTEPA)-induced toxicity in vitro and in vivo. Cancer Res, 61, pp. 5116-5125.
49. Bol, S. A., van Steeg, H., van Oostrom, C. T., Tates, A. D., Vrieling, H. and de Groot, A. J. (1999) Nucleotide excision repair modulates the cytotoxic and mutagenic effects of N-n-butyl-N-nitrosourea in cultured mammalian cells as well as in mouse splenocytes in vivo. Mutagenesis, 14, pp. 317-322.
50. Krokan, H. E., Nilsen, H., Skorpen, F., Otterlei, M. and Slupphaug, G. (2000) Base excision repair of DNA in mammalian cells. FEBS Lett, 476, pp. 73-77.
51. Ye, N., Holmquist, G. P. and O'Connor, T. R. (1998) Heterogeneous repair of N-methylpurines at the nucleotide level in normal human cells. J Mol Biol, 284, pp. 269-285.
52. Neto, J B Cabral, Cabral, R. E., Margot, A., Page, F Le, Sarasin, A. and Gentil, A. (1994) Coding properties of a unique apurinic/apyrimidinic site replicated in mammalian cells. J Mol Biol, 240, pp. 416-420.
53. Karran, P., Offman, J. and Bignami, M. (2003) Human mismatch repair, drug-induced DNA damage, and secondary cancer. Biochimie, 85, pp. 1149-1160.
54. Seedhouse, C. and Russell, N. (2007) Advances in the understanding of susceptibility to treatment-related acute myeloid leukaemia. Br J Haematol, 137, pp. 513-529.
55. Casorelli, I., Offman, J., Mele, L., Pagano, L., Sica, S. and D'Errico, M. (2003) Drug treatment in the development of mismatch repair defective acute leukemia and myelodysplastic syndrome. DNA Repair (Amst), 2, pp. 547-559.
56. Ben-Yehuda, D., Krichevsky, S., Caspi, O., Rund, D., Polliack, A. and Abeliovich, D. (1996) Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood, 88, pp. 4296-4303.
57. Sheikhha, M. H., Tobal, K. and Yin, J A Liu (2002) High level of microsatellite instability but not hypermethylation of mismatch repair genes in therapy-related and secondary acute myeloid leukaemia and myelodysplastic syndrome. Br J Haematol, 117, pp. 359-365.
58. Baumann, P., Benson, F. E. and West, S. C. (1996) Human Rad51 protein promotes ATP-dependent homologous pairing and strand transfer reactions in vitro. Cell, 87, pp. 757-766.
59. Bishop, D. K., Ear, U., Bhattacharyya, A., Calderone, C., Beckett, M. and Weichselbaum, R. R. (1998) Xrcc3 is required for assembly of Rad51 complexes in vivo. J Biol Chem, 273, pp. 21482-21488.
60. Wiese, C., Collins, D. W., Albala, J. S., Thompson, L. H., Kronenberg, A. and Schild, D. (2002) Interactions involving the Rad51 paralogs Rad51C and XRCC3 in human cells. Nucleic Acids Res, 30, pp. 1001-1008.
61. Sonoda, E., Sasaki, M. S., Buerstedde, J. M., Bezzubova, O., Shinohara, A. and Ogawa, H. (1998) Rad51-deficient vertebrate cells accumulate chromosomal breaks prior to cell death. EMBO J, 17, pp. 598-608.
62. Tebbs, R. S., Zhao, Y., Tucker, J. D., Scheerer, J. B., Siciliano, M. J. and Hwang, M. (1995) Correction of chromosomal instability and sensitivity to diverse mutagens by a cloned cDNA of the XRCC3 DNA repair gene. Proc Natl Acad Sci USA, 92, pp. 6354-6358.
63. Seedhouse, C., Faulkner, R., Ashraf, N., Das-Gupta, E. and Russell, N. (2004) Polymorphisms in genes involved in homologous recombination repair interact to increase the risk of developing acute myeloid leukemia. Clin Cancer Res, 10, pp. 2675-2680.
64. Brem, R. and Hall, J. (2005) XRCC1 is required for DNA single-strand break repair in human cells. Nucleic Acids Res, 33, pp. 2512-2520.
65. Seedhouse, C., Bainton, R., Lewis, M., Harding, A., Russell, N. and Das-Gupta, E. (2002) The genotype distribution of the XRCC1 gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia. Blood, 100, pp. 3761-3766.
66. Allan, J. M., Smith, A. G., Wheatley, K., Hills, R. K., Travis, L. B., Hill, D. A., Swirsky, D. M., Morgan, G. J. and Wild, C. P. (2004) Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood, 104, pp. 3872-3877.
67. Smith, A. G., Worrillow, L. J. and Allan, J. M. (2007) A common genetic variant in XPD associates with risk of 5q- and 7q-deleted acute myeloid leukemia. Blood, 109, pp. 1233-1236.
68. Worrillow, L. J., Travis, L. B., Smith, A. G., Rollinson, S., Smith, A. J. and Wild, C. P. (2003) An intron splice acceptor polymorphism in hMSH2 and risk of leukemia after treatment with chemotherapeutic alkylating agents. Clin Cancer Res, 9, pp. 3012-3020.
69. Zink, D., Mayr, C., Janz, C. and Wiesmuller, L. (2002) Association of p53 and MSH2 with recombinative repair complexes during S phase. Oncogene, 21, pp. 4788-4800.
70. Alani, E., Lee, S., Kane, M. F., Griffith, J. and Kolodner, R. D. (1997) Saccharomyces cerevisiae MSH2, a mispaired base recognition protein, also recognizes Holliday junctions in DNA. J Mol Biol, 265, pp. 289-301.
71. Kelly, K. M. and Perentesis, J. P. (2002) Polymorphisms of drug metabolizing enzymes and markers of genotoxicity to identify patients with Hodgkin's lymphoma at risk of treatment-related complications. Ann Oncol, 13, pp. 34-39.
72. Allan, J. M., Wild, C. P., Rollinson, S., Willett, E. V., Moorman, A. V., Dovey, G. J., Roddam, P. L., Roman, E., Cartwright, R. A. and Morgan, G. J. (2001) Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc Natl Acad Sci USA, 98, pp. 11592-11597.
73. Larson, R. A., Wang, Y., Banerjee, M., Wiemels, J., Hartford, C. and Beau, M M Le (1999) Prevalence of the inactivating 609C→T polymorphism in the NAD(P)H:qUinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood, 94, pp. 803-807.
74. Felix, C. A., Walker, A. H., Lange, B. J., Williams, T. M., Winick, N. J., Cheung, N. K., Lovett, B. D., Nowell, P. C., Blair, I. A. and Rebbeck, T. R. (1998) Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci USA, 95, pp. 13176-13181.
75. Rund, D., Krichevsky, S., Bar-Cohen, S., Goldschmidt, N., Kedmi, M. and Malik, E. (2005) Therapy-related leukemia: Clinical characteristics and analysis of new molecular risk factors in 96 adult patients. Leukemia, 19, pp. 1919-1928.
76. Blanco, J. G., Edick, M. J., Hancock, M. L., Winick, N. J., Dervieux, T. and Amylon, M. D. (2002) Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies. Pharmacogenetics, 12, pp. 605-611.
77. Bolufer, P., Collado, M., Barragan, E., Calasanz, M. J., Colomer, D. and Tormo, M. (2007) Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia. Br J Haematol, 136, pp. 590-596.
78. Naoe, T., Takeyama, K., Yokozawa, T., Kiyoi, H., Seto, M. and Uike, N. (2000) Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/ myelodysplastic syndrome and de novo acute myeloid leukemia. Clin Cancer Res, 6, pp. 4091-4095.
79. Hayes, J. D. and Pulford, D. J. (1995) The glutathione S-transferase supergene family: Regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol, 30, pp. 445-600.
80. Sasai, Y., Horiike, S., Misawa, S., Kaneko, H., Kobayashi, M. and Fujii, H. (1999) Genotype of glutathione S-transferase and other genetic configurations in myelodysplasia. Leuk Res, 23, pp. 975-981.
81. Woo, M. H., Shuster, J. J., Chen, C., Bash, R. O., Behm, F. G., Camitta, B. and Felix, C. A. (2000) Glutathione S-transferase genotypes in children who develop treatment-related acute myeloid malignancies. Leukemia, 14, pp. 232-237.
82. Davies, S. M., Robison, L. L., Buckley, J. D., Tjoa, T., Woods, W. G. and Radloff, G. A. (2001) Glutathione S-transferase polymorphisms and outcome of chemotherapy in childhood acute myeloid leukemia. J Clin Oncol, 19, pp. 1279-1287.
83. Jackson, S. P. (2002) Sensing and repairing DNA double-strand breaks. Carcinogenesis, 23, pp. 687-696.
84. Sandoval, A., Consoli, U. and Plunkett, W. (1996) Fludarabine-mediated inhibition of nucleotide excision repair induces apoptosis in quiescent human lymphocytes. Clin Cancer Res, 2, pp. 1731-1741.
85. Yamauchi, T., Nowak, B. J., Keating, M. J. and Plunkett, W. (2001) DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res, 7, pp. 3580-3589.
86. Li, L., Liu, X., Glassman, A. B., Keating, M. J., Stros, M. and Plunkett, W. (1997) Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced DNA adducts in vitro. Cancer Res, 57, pp. 1487-1494.
87. de Vries, J. F., Falkenburg, J. H., Willemze, R. and Barge, R. M. (2006) The mechanisms of Ara-C-induced apoptosis of resting B-chronic lymphocytic leukemia cells. Haematologica, 91, pp. 912-919.
88. Kufe, D. W., Major, P. P., Egan, E. M. and Beardsley, G. P. (1980) Correlation of cytotoxicity with incorporation of ara-C into DNA. J Biol Chem, 255, pp. 8997-8900.
89. O'Byrne, K. J., Philip, P. A., Propper, D. J., Braybrooke, J. P., Saunders, M. P. and Bates, N. P. (1999) A phase II study of the modulation of 5-fluorouracil and folinic acid with high-dose infusional hydroxyurea in metastatic colorectal carcinoma. Ann Oncol, 10, pp. 981-983.
90. Wollman, M. R., Penchansky, L. and Shekhter-Levin, S. (1996) Transient 7q- in association with megaloblastic anemia due to dietary folate and vitamin B12 deficiency. J Pediatr Hematol Oncol, 18, pp. 162-165.
91. Eto, I. and Krumdieck, C. L. (1986) Role of vitamin B12 and folate deficiencies in carcinogenesis. Adv Exp Med Biol, 206, pp. 313-330.
92. Robien, K. and Ulrich, C. M. (2003) 5,10-Methylenetetrahydrofolate reductase polymorphisms and leukemia risk: A HuGE minireview. Am J Epidemiol, 157, pp. 571-582.
93. Branda, R. F., Hacker, M., Lafayette, A., Nigels, E., Sullivan, L. and Nicklas, J. A. (1998) Nutritional folate deficiency augments the in vivo mutagenic and lymphocytotoxic activities of alkylating agents. Environ Mol Mutagen, 32, pp. 33-38.
94. Branda, R. F. and Blickensderfer, D. B. (1993) Folate deficiency increases genetic damage caused by alkylating agents and gamma-irradiation in Chinese hamster ovary cells. Cancer Res, 53, pp. 5401-5408.
95. Holden, S. A., Teicher, B. A., Robinson, M. F., Northey, D. and Rosowsky, A. (1995) Antifolates can potentiate topoisomerase II inhibitors in vitro and in vivo. Cancer Chemother Pharmacol, 36, pp. 165-171.
96. Shapiro, S., Hughes, G., Al-Obaidi, M. J., O'Reilly, E., Ramesh, S. and Smith, J. (2007) Acute myeloid leukaemia secondary to treatment with capecitabine for metastatic colorectal cancer. Eur J Haematol, 78, pp. 543-544.
97. Linassier, C., Barin, C., Calais, G., Letortorec, S., Bremond, J. L. and Delain, M. (2000) Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy. Ann Oncol, 11, pp. 1289-1294.
98. de Jonge, R., Hooijberg, J. H., van Zelst, B. D., Jansen, G., van Zantwijk, C. H. and Kaspers, G. J. (2005) Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia. Blood, 106, pp. 717-720.
99. Etienne, M. C., Formento, J. L., Chazal, M., Francoual, M., Magne, N. and Formento, P. (2004) Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenetics, 14, pp. 785-792.
100. Frosst, P., Blom, H. J., Milos, R., Goyette, P., Sheppard, C. A. and Matthews, R. G. (1995) A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet, 10, pp. 111-113.
101. Weisberg, I. S., Jacques, P. F., Selhub, J., Bostom, A. G., Chen, Z. and Ellison, R Curtis (2001) The 1298A → C polymorphism in methylenetetrahydrofolate reductase (MTHFR): In vitro expression and association with homocysteine. Atherosclerosis, 156, pp. 409-415.
102. Lievers, K. J., Boers, G. H., Verhoef, P., Heijer, M den, Kluijtmans, L. A. and van der Put, N. M. (2001) A second common variant in the methylenetetrahydrofolate reductase (MTHFR) gene and its relationship to MTHFR enzyme activity, homocysteine, and cardiovascular disease risk. J Mol Med, 79, pp. 522-528.
103. Sohn, K. J., Croxford, R., Yates, Z., Lucock, M. and Kim, Y. I. (2004) Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst, 96, pp. 134-144.
104. Jakobsen, A., Nielsen, J. N., Gyldenkerne, N. and Lindeberg, J. (2005) Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol, 23, pp. 1365-1369.
105. Shrubsole, M. J., Shu, X. O., Ruan, Z. X., Cai, Q., Cai, H. and Niu, Q. (2005) MTHFR genotypes and breast cancer survival after surgery and chemotherapy: A report from the Shanghai Breast Cancer Study. Breast Cancer Res Treat, 91, pp. 73-79.
106. Guillem, V. M., Collado, M., Terol, M. J., Calasanz, M. J., Esteve, J. and Gonzalez, M. (2007) Role of MTHFR (677, 1298) haplotype in the risk of developing secondary leukemia after treatment of breast cancer and hematological malignancies. Leukemia, 21, pp. 1413-1422.
107. Stam, R. W., Hubeek, I., Boer, M L den, Buijs-Gladdines, J. G., Creutzig, U. and Kaspers, G. J. (2006) MLL gene rearrangements have no direct impact on Ara-C sensitivity in infant acute lymphoblastic leukemia and childhood M4/M5 acute myeloid leukemia. Leukemia, 20, pp. 179-182.
108. Huang, Y., Fang, Y., Wu, J., Dziadyk, J. M., Zhu, X. and Sui, M. (2004) Regulation of Vinca alkaloid-induced apoptosis by NF-kappaB/IkappaB pathway in human tumor cells. Mol Cancer Ther, 3, pp. 271-277.
109. Pickell, L., Tran, P., Leclerc, D., Hiscott, J. and Rozen, R. (2005) Regulatory studies of murine methylenetetrahydrofolate reductase reveal two major promoters and NF-kappaB sensitivity. Biochim Biophys Acta, 1731, pp. 104-114.
110. Collado, M., Barragan, E., Bolufer, P., Calasanz, M. J., Larrayoz, M. J. and Colomer, D. (2005) Lack of association of CYP3A4-V polymorphism with the risk of treatment-related leukemia. Leuk Res, 29, pp. 595-597.
111. Hake, C. R., Graubert, T. A. and Fenske, T. S. (2007) Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients?. Bone Marrow Transplant, 39, pp. 59-70.